In this episode of Let's Combinate, host Subhi Saadeh delves into the significance of ICH Q12 for the pharmaceutical industry, especially concerning established conditions and drug-device combination products. Subhi explains how Q12 enhances lifecycle management, streamlines post-approval changes, and improves regulatory alignment. He breaks down critical concepts such as established conditions, product lifecycle management (PLCM), and post-approval change management protocols (PACMPs). Subhi outlines the benefits and challenges of adopting ICH Q12 and encourages listeners to familiarize themselves with its guidelines.
00:00 Introduction and Welcome
00:31 Topic Overview: ICH Q12 and Established Conditions
01:01 Understanding ICH Q12: Life Cycle Management
Podden och tillhörande omslagsbild på den här sidan tillhör Subhi Saadeh. Innehållet i podden är skapat av Subhi Saadeh och inte av, eller tillsammans med, Poddtoppen.
